APA (7th ed.) Citation

MG, L., JY, K., J, J., J, T., S, D., A, D., . . . DM, P. (2025). Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study. Advances in therapy, 42(3), 1582. https://doi.org/10.1007/s12325-024-03100-8

Chicago Style (17th ed.) Citation

MG, Lebwohl, et al. "Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study." Advances in Therapy 42, no. 3 (2025): 1582. https://doi.org/10.1007/s12325-024-03100-8.

MLA (9th ed.) Citation

MG, Lebwohl, et al. "Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study." Advances in Therapy, vol. 42, no. 3, 2025, p. 1582, https://doi.org/10.1007/s12325-024-03100-8.